# Amgen Inc.

> Amgen Inc. is a VC fund backing Health Care and Biotechnology. See 20 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Thousand Oaks, United States
- Total investments: 20
- Last investment: Jan 2024
- Lead investor: 35%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/amgen
- X (Twitter): https://twitter.com/amgen
- Website: http://www.amgen.com
- Facebook: https://www.facebook.com/amgenbiotech

Amgen Inc. is a VC fund in Thousand Oaks focused on Health Care and Biotechnology. Amgen is a biotechnology company that develops and manufactures human therapeutics for various illnesses and diseases. The company is values-based and deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious diseases. They offer products for treating illness in the areas ofoncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience.

## Contacts

5 contacts available for Amgen Inc.. Shizune tracks 13 team members at Amgen Inc.. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/amgen?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 10 | 50% |
| Biotechnology | 10 | 50% |
| Medical | 7 | 35% |
| Health Diagnostics | 5 | 25% |
| Therapeutics | 2 | 10% |

28 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 4 | 20% |
| Series B | 3 | 15% |
| Corporate Round | 3 | 15% |
| Series A | 2 | 10% |
| Post-IPO Equity | 2 | 10% |

9 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 11 | 55% |
| China | 1 | 5% |
| Israel | 1 | 5% |
| Latvia | 1 | 5% |
| Germany | 1 | 5% |

6 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Judith C. Pelham | Board of Director | 0 | https://shizune.co/investors/profile/judith-c-pelham |
| Vance Coffman | Board of Director | 0 | https://shizune.co/investors/profile/vance-d-coffman |
| Alexander Kamb | Senior Vice President, Discovery Research | 0 | https://shizune.co/investors/profile/alexander-kamb |
| David Haddad | Director of Product Management | 0 | https://shizune.co/investors/profile/david-haddad-2 |
| Elliott Sigal | Co-Chair, Scientific Advisory Board | 2 | https://shizune.co/investors/profile/elliott-sigal |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Quantinuum | Quantinuum is a quantum company dedicated to the advancement of quantum computers and the development of software solutions. Quantinuum's technology spearheads advancements in materials discovery, cybersecurity, and next-generation quantum AI. The company has nearly 500 professionals, including over 370 scientists and engineers, Quantinuumtakes the helm in driving the quantum computing revolution globally. | $300M | Corporate Round | Jan 15, 2024 |  |
| Quantinuum | Quantinuum is a quantum company dedicated to the advancement of quantum computers and the development of software solutions. Quantinuum's technology spearheads advancements in materials discovery, cybersecurity, and next-generation quantum AI. The company has nearly 500 professionals, including over 370 scientists and engineers, Quantinuumtakes the helm in driving the quantum computing revolution globally. | $300M | Series A | Jan 15, 2024 |  |
| Generate Biomedicines | Generate Biomedicines is a biotechnological company focusing on creating breakthrough medicines. | $273M | Series C | Sep 14, 2023 |  |
| Neumora Therapeutics | Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience. | $112M | Series B | Oct 11, 2022 |  |
| Accure Health | Accure Health ("Accure") is a privately held, next-generation precision medicine company. Accure is focused on developing AI-powered solutions that leverage patients' biomarker profiles to enable precision therapies delivered to the right cells for the right patients. Accure’s motto is "Cure through Accuracy". |  |  | Mar 01, 2022 |  |
| Accure Health | Accure Health ("Accure") is a privately held, next-generation precision medicine company. Accure is focused on developing AI-powered solutions that leverage patients' biomarker profiles to enable precision therapies delivered to the right cells for the right patients. Accure’s motto is "Cure through Accuracy". |  | Non-equity Assistance | Jan 01, 2022 |  |
| Neumora Therapeutics | Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience. | $100M | Corporate Round | Oct 07, 2021 |  |
| Jasper Therapeutics | Jasper is a biotechnology company focused on enabling safer conditioning agents to allow for expanded use of curative therapy with stem cell transplants and gene therapies. Jasper’s lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a stem celltransplant. | $100M | Post-IPO Equity | Sep 27, 2021 |  |
| SomaLogic | SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscantechnology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado. | $81M | Series A | Dec 23, 2020 |  |
| Science 37 | Science 37 is making the promise of virtual trials the new reality. By engaging with patients from the comfort of their own home, the company provides access to patients who can never be reached by traditional site-based research models. Its virtual model has proven to enroll faster, retain patients at a higher rate, and reach a more representativepatient population. Science 37 has conducted more virtual (or decentralized), interventional trials than any other company, using an expansive, in-house network of telemedicine investigators and home-health nurses. The company's research is powered by the industry’s most comprehensive, fully integrated clinical trial platform purpose-built to conduct virtual trials. | $40M | Venture - Series Unknown | Aug 20, 2020 |  |

10 of 20 investments shown.

## Co-investors
- [Amgen](https://shizune.co/investors/profile/amgen-2) — VC Fund, 18 deals together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 2 deals together
- [Honeywell](https://shizune.co/investors/profile/honeywell) — VC Fund, 2 deals together
- [JP Morgan Chase](https://shizune.co/investors/profile/jpmorgan-chase-co) — VC Fund, 2 deals together
- [Mitsui & Co](https://shizune.co/investors/profile/mitsui) — VC Fund, 2 deals together
- [Mubadala Capital Ventures](https://shizune.co/investors/profile/mubadala-ventures) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

## FAQ

### What does Amgen Inc. invest in?

Amgen Inc. invests primarily in Health Care, Biotechnology and Medical startups, most often at Funding Round and Series B stage. Most of the 20 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Amgen Inc.?

Public channels for Amgen Inc. include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Amgen Inc.?

The team at Amgen Inc. includes Judith C. Pelham (Board of Director), Vance Coffman (Board of Director) and Alexander Kamb (Senior Vice President, Discovery Research), among 13 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co